ClinicalTrials.gg
RecruitingNCT06319235Updated Mar 19, 2024

Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®

A Phase 1/2 interventional study of IMP and Placebo in Surgical Site Infection, Staphylococcus Aureus Infection and Pseudomonas Aeruginosa Infection, sponsored by MB PHARMA s.r.o.. Recruiting at 1 site in Czechia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-03-19.

Sponsored by MB PHARMA s.r.o. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Registered 4 months after the study started (first participant enrolled Oct 2023, registered Mar 2024).
  • Started Oct 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

DUOFAG® is a phage cocktail containing bacteriophages active against Staphylococcus aureus and Pseudomonas aeruginosa. It is an investigational medicinal product for the treatment of surgical site infections caused by S. aureus and P. aeruginosa.

The primary objective of the study is to demonstrate the safety of DUOFAG® and the clinical and microbiological change within 10 weeks after the start of treatment or until healing.

Read the detailed description

The study population will be recruited in two cohorts. The microbiological population of the wound will be evaluated to analyze the effect of the treatment. If the safety profile and treatment effect are going to be satisfactory, the recruitment will proceed with Cohort 2.

In both cohorts, the Investigational Medicinal Product (IMP) or placebo (the randomization ratio will be 1:1) will be applied twice a day for two weeks or until the commencement of healing.

Patients will receive the standard of care during the whole study duration. No concomitant treatment is planned during the treatment period.

The Adverse Events will be recorded on basis of an open interview without soliciting questions, and clinical observation. In case of occurrence of an adverse event (AE) with moderate or severe intensity possibly related to IMP, the treatment will be stopped, and the AE will be followed up until resolution.

Adverse Event descriptions, their severity (mild, moderate, or severe), duration and their perceived relationship to the study medication (probable, possible, unlikely, not related, and not sure) will be recorded.

The mLUMT (modified Leg Ulcer Measurement Tool) total score and individual item scores change since the baseline visit will be recorded.

Time from the start of the study treatment until the bacterial infection eradication - i. e. the swab sample is negative on S. aureus and/or P. aeruginosa will be recorded.

Time from the start of the study treatment until the wound is closed/healed (as assessed by investigator) will be recorded.

02

Conditions studied

  • Surgical Site Infection
  • Staphylococcus Aureus Infection
  • Pseudomonas Aeruginosa Infection
  • Bacterial Infections
  • Surgical Wound Infection

Keywords

  • Phage Therapy
  • Staphylococcus aureus
  • Pseudomonas aeruginosa
  • Surgical site infection
  • Bacteriophage
  • Bacterial infections
03

In context

Surgical Wound Infection

746 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.

This study's planned enrollment of 52 is below the median of 200 across 583 interventional studies indexed under Surgical Wound Infection.

Browse Surgical Wound Infection studies →

Lead sponsor

This is the only study on the registry with MB PHARMA s.r.o. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with surgical wound infection and/or dehiscence
  • Wound infected by S. aureus and/or P. aeruginosa according to wound swab.
  • Wound in the groin or any other skin fold as per Investigator's discretion.
  • Signed Form, approved by the ethical committee and competent authority.
  • The age between 18 and 75 years.
  • Patients able and willing to comply with study procedures.
  • There are no for planned concomitant medication.
  • Persisting symptoms of bacterial infection \< 3 weeks since the surgery.
  • Women of must take highly effective measures since the study start and one month after the treatment administration at a minimum.

Exclusion criteria

Exclusion Criteria:

  • History of an organ or bone marrow transplantation.
  • Any disease.
  • Uncompensated diabetes mellitus, confirmed by the concentration of >60 mmol/mol (6%).
  • Systematic therapy.
  • treatment \<1 year before the Baseline visit.
  • COVID-19 infection \<3 months before the Baseline visit, any signs of post-COVID syndrome.
  • Pregnancy or planning to become pregnant during the study.
  • Breastfeeding.
  • Participation in another clinical study.
  • to the IMP or placebo.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    Investigational arm

    DUOFAG® (the investigational medicinal product - IMP) will be administered twice a day for two weeks. DUOFAG® will be sprayed on the surgical wound. The phage titers of each bacteriophage in DUOFAG® is ≥ 10 000 000 PFU/mL (PFU = plaque forming units).

    Drug: IMP

  • Placebo comparator
    Control arm

    Placebo (physiological saline solution - 0.9% sodium chloride solution) will be administered twice a day for two weeks. Placebo will be sprayed on the surgical wound.

    Drug: Placebo

Interventions

  • DrugIMP

    DUOFAG® is a phage cocktail (cutaneous liquid) manufactured by MB PHARMA s.r.o. and it contains bacteriophages active against Staphylococcus aureus and Pseudomonas aeruginosa.

    Also known as: DUOFAG®

  • DrugPlacebo

    0.9% Sodium Chloride Injection solution was manufactured by B. Braun Melsungen AG. Marketing authorization number assigned from the State Institute for drug control (Czech Republic): 76/847/92-B/C

    Also known as: 0.9% Sodium Chloride Injection

06

What researchers measure

Primary outcomes

  1. Primary endpoint - Cohort 1

    The endpoint will be the frequency of all (local and systemic) reactions with suspected or confirmed relation to IMP.

    Time frame: 10 weeks (the maximum duration)

  2. Primary endpoint - pooled Cohorts 1 & 2

    Time to commencement of healing.

    Time frame: 10 weeks (the maximum duration)

Secondary outcomes

  1. Safety endpoints (assessed in pooled Cohorts 1 & 2)

    The frequency of the following symptoms following the IMP application will be evaluated: local reactions, systemic reactions.

    Time frame: 10 weeks (the maximum duration)

  2. Microbiological endpoints (assessed in pooled Cohort 1 and Cohort 2)

    Change of the microbiological profile of the wound assessed by swab.

    Time frame: 2 weeks (the maximum duration)

  3. Clinical efficacy endpoints

    The mLUMT total score change since Baseline, time since the start of the study treatment until the bacterial infection eradication, time since the start of the study treatment until the granulation process in the wound has started, time since the start of the study treatment until the wound is closed as assessed by Investigator.

    Time frame: 10 weeks (the maximum duration)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2023 (actual). Primary completion is estimated for Dec 2025, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2024
First posted
Mar 19, 2024
StartActual
Oct 27, 2023
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Mar 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06319235
Lead sponsor
MB PHARMA s.r.o.
Responsible party
Sponsor
First posted
Mar 19, 2024
Start date
Oct 27, 2023
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Mar 19, 2024

Study contacts

Dana Štveráková, Ph.D.
Contact
stverakova@mbph.cz
+420 604 912 940
Monika Peichlová, Ing.
Contact
peichlova@mbph.cz
+420 777 487 400
Robert Staffa, prof.
principal investigator · St. Anne's University Hospital Brno

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inosine Monophosphate

Start the discussion